瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效观察

Clinical effect of rosuvastatin versus atorvastatin in treatment of coronary heart disease

目的对比对瑞舒伐他汀与阿托伐他汀治疗冠心病的临床疗效。方法210例冠心病患者随机分为观察组和对照组，各105例。对照组服用阿托伐他汀，观察组服用瑞舒伐他汀，观察2组治疗前后血脂参数、血流介导性血管舒张功能（FMD）、超敏c-反应蛋白（hs—CRP）变化。结果治疗后，2组LDL-C、TC、TG和血清hs—CRP水平均显著下降，HDL-C水平和FMD值显著上升，差异有统计学意义（P〈0．05或P〈0．01）。组间比较，观察组LDL-C、HDL-C、TC、TG、血清hs—CRP水平和FMD值改善优于对照组（P〈0．05或P〈0．01）。结论瑞舒伐他汀治疗冠心病效果优于阿托伐他汀，调节血脂功能和改善心功能更为理想。

Objective To compare the clinical effects of rosuvastatin versus atorvastatin in treatment of coronary heart disease. Methods A total of 210 patients with coronary heart disease were randomly divided into study group （ n = 105 ） and control group （ n -- 105 ）. The control group was giv- en atorvastatin, and study group was treated with rosuvastatin. The low-density lipoprotein cholesterol （LDL-C）, high-density lipoprotein cholesterol （HDL-C）, total cholesterol （TC）, Triglyceride （TG）, flow-mediated dilatation （FMD） and hs-CRP were compared between two groups. Results After treatment, the levels of LDL-C, TC, TG and serum hs-CRP were dropped, LDL-C and FMD were increased in both group, with a significant difference （P 〈0.05, P 〈0.01 ）. The study group re- ceived a better improvement in LDL-C, HDL-C, TC, TG, FMD and serum hs-CRP compared with the control group （P 〈 0.05, P 〈 0.01 ）. Conclusion Rosuvastatin, with a better adjustment of lipid metabolism, shows a better effect in treatment of coronary heart disease.